ZD-4190 is primarily used in the field of oncology research as a potent and selective inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2). Its application is focused on studying angiogenesis, the process by which new blood vessels form from pre-existing vessels. By inhibiting VEGFR-2, ZD-4190 effectively blocks the signaling pathways that promote tumor growth and metastasis. This makes it a valuable tool in preclinical studies aimed at understanding cancer progression and developing targeted anti-cancer therapies. Researchers utilize ZD-4190 to evaluate its potential in reducing tumor vascularization and improving outcomes in experimental models of various cancers.